204 related articles for article (PubMed ID: 8771196)
1. The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution.
Zhang Y; Bond CS; Bailey S; Cunningham ML; Fairlamb AH; Hunter WN
Protein Sci; 1996 Jan; 5(1):52-61. PubMed ID: 8771196
[TBL] [Abstract][Full Text] [Related]
2. The structure of Trypanosoma cruzi trypanothione reductase in the oxidized and NADPH reduced state.
Lantwin CB; Schlichting I; Kabsch W; Pai EF; Krauth-Siegel RL
Proteins; 1994 Feb; 18(2):161-73. PubMed ID: 8159665
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors.
Bond CS; Zhang Y; Berriman M; Cunningham ML; Fairlamb AH; Hunter WN
Structure; 1999 Jan; 7(1):81-9. PubMed ID: 10368274
[TBL] [Abstract][Full Text] [Related]
4. Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.
Stoll VS; Simpson SJ; Krauth-Siegel RL; Walsh CT; Pai EF
Biochemistry; 1997 May; 36(21):6437-47. PubMed ID: 9174360
[TBL] [Abstract][Full Text] [Related]
5. Structure of trypanothione reductase from Crithidia fasciculata at 2.6 A resolution; enzyme-NADP interactions at 2.8 A resolution.
Bailey S; Fairlamb AH; Hunter WN
Acta Crystallogr D Biol Crystallogr; 1994 Mar; 50(Pt 2):139-54. PubMed ID: 15299452
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis and molecular docking of trypanocidal aryloxy-quinones in trypanothione and glutathione reductases: a comparison with biochemical data.
Vera B; Vázquez K; Mascayano C; Tapia RA; Espinosa V; Soto-Delgado J; Salas CO; Paulino M
J Biomol Struct Dyn; 2017 Jun; 35(8):1785-1803. PubMed ID: 27232454
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the Trypanosoma cruzi trypanothione reductase.mepacrine complex.
Jacoby EM; Schlichting I; Lantwin CB; Kabsch W; Krauth-Siegel RL
Proteins; 1996 Jan; 24(1):73-80. PubMed ID: 8628734
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis.
Waksman G; Krishna TS; Williams CH; Kuriyan J
J Mol Biol; 1994 Feb; 236(3):800-16. PubMed ID: 8114095
[TBL] [Abstract][Full Text] [Related]
9. X-ray structure of trypanothione reductase from Crithidia fasciculata at 2.4-A resolution.
Kuriyan J; Kong XP; Krishna TS; Sweet RM; Murgolo NJ; Field H; Cerami A; Henderson GB
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8764-8. PubMed ID: 1924336
[TBL] [Abstract][Full Text] [Related]
10. Trypanothione reductase from Trypanosoma cruzi. Purification and characterization of the crystalline enzyme.
Krauth-Siegel RL; Enders B; Henderson GB; Fairlamb AH; Schirmer RH
Eur J Biochem; 1987 Apr; 164(1):123-8. PubMed ID: 3549299
[TBL] [Abstract][Full Text] [Related]
11. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH
J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking of a series of peptidomimetics in the trypanothione binding site of T. cruzi trypanothione reductase.
da Rocha Pita SS; Cirino JJ; de Alencastro RB; Castro HC; Rodrigues CR; Albuquerque MG
J Mol Graph Model; 2009 Nov; 28(4):330-5. PubMed ID: 19766515
[TBL] [Abstract][Full Text] [Related]
13. Active site of trypanothione reductase. A target for rational drug design.
Hunter WN; Bailey S; Habash J; Harrop SJ; Helliwell JR; Aboagye-Kwarteng T; Smith K; Fairlamb AH
J Mol Biol; 1992 Sep; 227(1):322-33. PubMed ID: 1522596
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of antimony treatment in leishmaniasis.
Baiocco P; Colotti G; Franceschini S; Ilari A
J Med Chem; 2009 Apr; 52(8):2603-12. PubMed ID: 19317451
[TBL] [Abstract][Full Text] [Related]
15. Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds.
Jockers-Scherübl MC; Schirmer RH; Krauth-Siegel RL
Eur J Biochem; 1989 Mar; 180(2):267-72. PubMed ID: 2647489
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of the trypanothione reductase gene from Crithidia fasciculata and Trypanosoma brucei: comparison with other flavoprotein disulphide oxidoreductases with respect to substrate specificity and catalytic mechanism.
Aboagye-Kwarteng T; Smith K; Fairlamb AH
Mol Microbiol; 1992 Nov; 6(21):3089-99. PubMed ID: 1453951
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a trypanothione-dependent peroxidase system in Trypanosoma cruzi.
Lopez JA; Carvalho TU; de Souza W; Flohé L; Guerrero SA; Montemartini M; Kalisz HM; Nogoceke E; Singh M; Alves MJ; Colli W
Free Radic Biol Med; 2000 Mar; 28(5):767-72. PubMed ID: 10754272
[TBL] [Abstract][Full Text] [Related]
18. Four crystal structures of the 60 kDa flavoprotein monomer of the sulfite reductase indicate a disordered flavodoxin-like module.
Gruez A; Pignol D; Zeghouf M; Covès J; Fontecave M; Ferrer JL; Fontecilla-Camps JC
J Mol Biol; 2000 May; 299(1):199-212. PubMed ID: 10860732
[TBL] [Abstract][Full Text] [Related]
19. Flavoprotein structure and mechanism. 5. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design.
Krauth-Siegel RL; Schöneck R
FASEB J; 1995 Sep; 9(12):1138-46. PubMed ID: 7672506
[TBL] [Abstract][Full Text] [Related]
20. The crystal structure of NADPH:ferredoxin reductase from Azotobacter vinelandii.
Sridhar Prasad G; Kresge N; Muhlberg AB; Shaw A; Jung YS; Burgess BK; Stout CD
Protein Sci; 1998 Dec; 7(12):2541-9. PubMed ID: 9865948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
